Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Jul 5 · above the Ichimoku cloud · RSI 53 · MACD below its signal
None of the 29 investors followed here reported a position in 2005.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 2005.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 14, 2025 | Qu (Jiguang)Chief Executive Officer | Acquisition at price 0.39 per share. | 580K | $226.66K |
| Nov 25, 2024 | Qu (Jiguang)Chief Executive Officer | Acquisition at price 0.45 per share. | 1.30M | $582.92K |
| Nov 19, 2024 | Qu (Jiguang)Chief Executive Officer | Acquisition at price 0.50 per share. | 400K | $199.36K |
| Nov 18, 2024 | Qu (Jiguang)Chief Executive Officer | Acquisition at price 0.48 per share. | 900K | $436.14K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.6 | -8.8 | -8.9 | -6.5 | 1.3 | -9.0 | 12.3 | 13.7 | 4.4 | -2.8 | −3.0% | ||
| 2025 | -11.4 | -0.6 | 1.9 | -8.4 | -0.7 | -5.1 | 11.9 | -8.7 | 2.8 | 6.2 | -1.0 | -7.8 | −21.2% |
| 2024 | -14.2 | 4.0 | 17.0 | -7.4 | -1.5 | -10.4 | -7.6 | -0.8 | 11.1 | -12.3 | -5.6 | 0.8 | −27.3% |
| 2023 | 13.0 | -3.5 | 0.6 | 15.6 | -11.9 | 3.7 | -12.8 | -4.4 | 8.9 | -5.5 | 12.6 | 2.3 | +14.6% |
| 2022 | -14.2 | 5.5 | -2.7 | 10.2 | -8.7 | 17.7 | 6.2 | -16.6 | -11.1 | -1.5 | 19.7 | 10.8 | +7.2% |
| 2021 | -6.6 | 1.0 | 9.7 | 5.7 | 7.7 | 34.5 | -28.1 | -3.0 | -13.0 | -11.9 | 5.1 | 3.1 | −8.2% |
| 2020 | 13.6 | -8.9 | -7.2 | -9.2 | -13.6 | 11.4 | -7.6 | 1.0 | -10.9 | -3.9 | 12.1 | -7.6 | −30.6% |
| 2019 | 21.2 | -1.0 | 4.9 | 1.5 | -15.9 | 13.3 | -0.4 | -1.3 | -10.7 | 5.8 | -6.1 | 2.4 | +8.8% |
| 2018 | 19.3 | 3.5 | 16.0 | 15.7 | 5.3 | 3.8 | -13.9 | -2.7 | 3.6 | -12.8 | 21.9 | -27.8 | +20.6% |
| 2017 | 1.2 | -2.4 | 26.6 | -3.6 | 1.0 | 6.0 | 8.2 | 4.9 | -1.4 | 3.9 | 18.6 | 9.3 | +94.7% |
| 2016 | 0.5 | 16.4 | 5.1 | 8.1 | -4.5 | -1.6 | -0.4 | 7.6 | -0.7 | -1.5 | -0.4 | -5.4 | +23.5% |
| 2015 | 2.0 | -9.1 | 2.7 | 1.5 | -12.8 | -6.0 | -17.4 | -4.3 | -17.9 | 6.6 | 1.0 | 1.5 | −43.8% |
| 2014 | 18.9 | 6.7 | 17.8 | 0.0 | -1.3 | -4.8 | 15.8 | 14.5 | -5.3 | 0.8 | -5.0 | -0.6 | +67.9% |
| 2013 | -5.2 | -1.8 | 10.7 | 1.7 | 3.7 | -2.0 | 5.7 | 3.1 | -2.6 | -19.2 | 1.0 | 0.0 | −7.8% |
| 2012 | 10.1 | 16.3 | 49.1 | 0.0 | 10.6 | 10.6 | -8.7 | 16.3 | 7.0 | 6.6 | 2.4 | 7.0 | +210.1% |
| 2011 | -10.1 | -5.4 | 13.0 | -11.5 | -11.9 | -4.7 | -14.8 | -15.2 | -36.8 | 23.0 | -7.7 | 6.0 | −60.8% |
| 2010 | -4.0 | 13.3 | 32.4 | 46.7 | -4.9 | 13.9 | -16.8 | -0.8 | 28.8 | -12.5 | -2.3 | -12.7 | +81.6% |
| 2009 | -3.5 | 5.5 | -8.6 | -6.6 | 17.2 | 65.5 | 21.9 | -14.5 | -15.0 | 29.4 | 27.3 | -10.7 | +119.3% |
| 2008 | -33.8 | 0.0 | -10.0 | 0.0 | -4.9 | -2.6 | -12.0 | -7.6 | -18.9 | -33.3 | 45.5 | 18.7 | −58.1% |
| 2007 | -2.2 | 0.6 | -4.4 | 17.0 | 38.0 | -1.8 | -5.4 | 389.1 | -81.1 | 29.4 | 29.1 | -4.2 | +109.2% |
SSY Group Limited, an investment holding company, researches, develops, manufactures, trades, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; research, development of biotechnology and related roducts; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. SSY Group Limited was founded in 1999 and is headquartered in Wan Chai, Hong Kong.
Buy / hold / sell counts
No recent headlines.